Country Pharmaceutical Situation Based on World Health Organization Indicators: Evidence from an Upper-Middle Income Country

سال انتشار: 1398
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 431

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

AECPMED02_055

تاریخ نمایه سازی: 28 بهمن 1398

چکیده مقاله:

Introduction: Evaluating the performance of national authorities has a pivotal role in the development of evidence-based policy making. Regarding the complexity of pharmaceutical sector and its serious impacts on public health, Food and Drug Administrations’ performance should be evaluated at regular intervals. This study aims to depict a comprehensive picture of Iranian pharmaceutical situation as well as its structural gaps. Methods: In this cross-sectional descriptive study, inspired by indicators proposed by world health organization (WHO), a checklist was developed with six component topics and 239 indicators. These topics consider the existence and performance of six key structures, including national drug policy (NDP), regulatory system, medicines supply system, medicine financing, production and trade, and rational use of drugs (RUD). Afterwards, the translation validity as well as face and content validity of the research tool was confirmed by relevant experts. The data were collected by referring to official documents and reports, as well as key informants in Iranian Food and Drug Administration (IFDA). Results and discussion: The scores for structures of IFDA according to the WHO indicators are 80% in NDP, 61.5% in regulatory system, 64.7% in medicines supply system, 84.8% in medicines financing, 60% in production and trade, and 71.7% in RUD. Conclusion: Considering the status of structures and processes, IFDA should attempt to provide an action plan commensurate with the NDP, modify the regulations in terms of its responsibilities and authorities, develop transparency and accountability in its offices, publish national essential medicines list, and revise motivational and punitive policies to develop RUD. References: -Morgan S, Kennedy J, Boothe K, McMahon M. Toward an understanding of high performance pharmaceutical policy systems: a Triple-A framework and example analysis. Open Health Serv Policy J. 2009;2(1). -Precious M, German V. WHO Operational Package for Assessing, Monitoring and Evaluating Country Pharmaceutical Situations. Geneva; 2007.

نویسندگان

Mohammad Peikanpour

Dept. of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Nazila Yousefi

Dept. of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Hossein Minaei

Dept. of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Payam Peymani

Health Policy Research Center, Institute of Health, Shiraz University of Medical Science, Shiraz, Iran

Farzad Peiravian

Dept. of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Javad Shamsaee

Dept. of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran